Surgery Partners, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 88/100
What the filing says
Surgery Partners amended its HealthSpan Partners merger agreement on November 9, 2026, increasing consideration from an undisclosed prior price to $25.00 per share in cash, implying ~$6.0 billion enterprise value. Stockholders (excluding Bain Capital affiliates) receive 10% per annum ticking fee if closing delays past March 1, 2027. Q3 2026 revenue declined 0.8% YoY to $815.3M; same-facility revenue grew 6.0%; Adjusted EBITDA was $132.7M. Merger expected to close Q1 2027 pending stockholder approval and regulatory clearance.
Why this rating
Deal valuation ($6B EV) is 2.3x company market cap ($2.6B), materially reshaping ownership/control. Price increase and ticking fee indicate validation. Operational softness (revenue -0.8% overall) and pending transaction halt guidance undermine confidence, but deal itself is transformational.
Tradability signal
NO TRADE
No trade: positive news with only -0.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.40% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $26.45 ▼ 0.97% | at our read · unknown $26.71 | +10 min · unknown $26.47 ▼ 0.90% | +30 min · unknown $26.55 ▼ 0.60% | +1 hr · unknown $26.44 ▼ 1.01% | +4 hrs · unknown $26.60 ▼ 0.41% |
The stock had already moved +0.98% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.